drugset / Trial / NCT02799095
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To better understand the safety and tolerability of ALKS 4230 in humans
Timeline
- Start
- 2016-09-14
- Primary completion
- 2023-03-27
- Completion
- 2023-08-02
Publications
- Calvo E, Boni V, Dumas O, Shin SJ, Rosen SD, Chaudhry A, Debruyne PR, He X, Vaishampayan UN, McDermott DF. Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial. J Immunother Cancer. 2025 Aug 4;13(8):e010777. doi: 10.1136/jitc-2024-010777.
- Vaishampayan UN, Muzaffar J, Winer I, Rosen SD, Hoimes CJ, Chauhan A, Spreafico A, Lewis KD, Bruno DS, Dumas O, McDermott DF, Strauss JF, Chu QS, Gilbert L, Chaudhry A, Calvo E, Dalal R, Boni V, Ernstoff MS, Velcheti V. Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). J Immunother Cancer. 2024 Nov 20;12(11):e010143. doi: 10.1136/jitc-2024-010143.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemvaleukin Alfa | Protein / enzyme biologic | 0.1 ug/kg | Intravenous |
| Subject | Nemvaleukin Alfa | Protein / enzyme biologic | 6 ug/kg | Intravenous |
| Subject | Nemvaleukin Alfa | Protein / enzyme biologic | 10 ug/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |